- Clinical Trial Data of Recombinant Human Albumin Injection (Oryza Sativa) was published in the journal "Gut" Recently, the R&D team of Healthgen has published groundbreaking research in GUT, a premier journal in gastroenterology and hepatology (Impact Factor: 25.8). The paper, titled "Rice-derived recombinant human serum albumin as an alternative to human plasma ... Posted by Site editor|2025-06-26 LearnMore
- First-in-Class: Recombinant Human Albumin Injection (Oryza Sativa) Approved by China NMPA Healthgen’s “Recombinant Human Albumin Injection(Oryza Sativa)” was approved by the China’s National Medical Products Administration (NMPA)on 18 July, 2025. Drug Name: Recombinant Human Albumin Injection (Oryza Sativa) Drug Approval No... Posted by Site editor|2025-07-18 LearnMore
- A powerful alternative to solve the issue of BSA impurity residue -plant-derived recombinant human serum albumin “Hywill™ OsrHSA” In the In Vitro Diagnosis ( IVD ) industry, BSA（Bovine serum albumin） has been one of the widely used raw materials. It plays an important role in various diagnostic methods, such as biochemical, chemiluminescence, mass spectrometry and other detection methods. However, BSA is ma... Posted by Site editor|2023-05-29 LearnMore
- Healthgen Biotech won the "Gold Award of the 2nd High-value Patent Competition of Hubei Province " April 20, 2022, the "2022 National Intellectual Property Publicity Week Launching Ceremony" and award ceremony of "The 2nd High-value Patent Competition of Hubei Province" hosted by the Hubei Provincial Intellectual Property Office were held at the Hubei Science and Technology Mu... Posted by Site editor|2022-04-20 LearnMore
- Phase II clinical study of plant-derived recombinant human serum albumin achieved phased results The HY1001 project (plant-derived Recombinant human serum albumin injection) of Wuhan Healthgen Biotechnology Corp. (hereinafter referred to as “Healthgen Biotech”), Phase II clinical study completed the enrollment of all subjects in the first cohort. On January 12, 2022, after ... Posted by Site editor|2022-01-14 LearnMore
Copyright ® Wuhan Healthgen Biotechnology Corp. All rights reserved. Terms and Conditions of Use
鄂ICP备12013293号-3
